EMCIFund

BrightEdge propels groundbreaking patient-centric solutions by investing in and supporting the most innovative startup companies to advance science, reduce disparities, and promote healthcare sustainability. BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society (ACS). Through our donor-funded ACS Impact Venture Fund (AIVF), we further ACS’s mission by investing in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate our vision of ending cancer as we know it, for everyone. About BrightEdge and The American Cancer Society BrightEdge is helping create a stream of alternate income to sustain the critical work being done across our pillars. Donations to BrightEdge become a sustainable source of financial support to the American Cancer Society, diversifying and modernizing the ACS’s income sources. Investment returns from the AIVF portfolio are both reinvested in AIVF to further support new and existing companies in the portfolio and additional proceeds are used to sustain ACS’s lifesaving programs in research, access, and health equity. BrightEdge investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment FrameworkTM (CIIFTM). BrightEdge builds on the American Cancer Society’s commitment to funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies. Our ability to translate scientific discoveries into accessible cures and solutions depends on investments in entrepreneurial for-profit companies that can validate, develop, and commercialize products and services at scale in the healthcare marketplace for people facing cancer. BrightEdge plays a unique role alongside traditional venture capital firms by addressing early-stage funding gaps, incubating high-impact companies, bringing system-level knowledge to companies at critical points in product development, and helping emerging companies access world-class intellectual and human capital as they grow. Learn how BrightEdge will help improve 1.5 million lives by investing in cancer-focused therapies and technologies in its most recent annual report and infographic.

At StartUp Health, we are impact-driven entrepreneurs and investors building a global army of thousands of Health Transformers collaborating to achieve health moonshots --- from ending cancer and curing disease, like diabetes and Alzheimer’s, to delivering quality care to everyone in the world regardless of location or income. We believe that investing in and supporting a diversified global portfolio of health moonshot companies is the key to improving the health and wellbeing of humanity, while also generating healthy financial returns for investors. Since 2012, we’ve made more than 400 investments in companies across 27 countries, and currently have a portfolio of 260+ active companies. We have a flexible, work-from-anywhere policy as our team is fully remote, with team members in NYC, San Francisco, Los Angeles, Baltimore, and Philadelphia. We are open to candidates across the U.S. Benefits include health insurance and long-term disability coverage, 401k with employer matching, employee stock options, and generous time off policy including paid holidays.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Droia invests in novel science and innovative approaches to bring promising drug candidates to patients, and accelerate their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. Droia has an in-house team of experts and drug development professionals who follow the portfolio companies closely and provide hands-on support. Droia invests in early financing rounds and incubates new companies. Operating from Luxembourg and Belgium, Droia invests globally. MAKING A DIFFERENCE Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives. BREAKTHROUGH FOCUS For biotech companies, ultimate success is measured in effective patient benefit. Promising therapies should have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed and the improvement in therapeutic benefits as compared to (expected) standard of care. We only invest in companies that are able, through their technology platforms or scientific insights, to go after previously unsolvable clinical problems. Companies should differentiate not only by way of innovation, but also in the way this innovation translates to clinical breakthrough. GETTING IT DONE Droia actively scouts for the best science and the best teams. Whether investing in an existing company or creating a new company, we actively participate in our portfolio companies’ development. Our team has deep and specialized experience in disease biology, translational science, clinical development and company building. We have built many companies from the ground up, supporting and complementing founders and management teams. Our team members dedicate their time to helping their companies, and will take on interim roles within companies to help them get off the ground faster. Our whole organization is geared towards doing what we do best: building great drug development companies.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

We invest in early-stage opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takeda’s R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. Our aim is to access and support therapeutic and platform innovation working closely with academic innovators, entrepreneurs and investors. We invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.